TTS Sam personal page - To The Moon

TTS Sam

TTS Sam

No personal profile

365Follow

10Followers

0Topic

0Badge

2022-10-10

Good

@Keeley:Stocks Technical Analysis #AMC #MSFT #AAPL

2022-07-07

Good

Oil Extends Its Decline, With Brent Crude Dropping Below $100 a Barrel

2022-05-05

Good

Nasdaq Bear Market: 3 Growth Stocks Down 64% (or More) Just Begging to Be Bought

2022-04-29

Good

Singapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit

2022-04-24

Good

Sorry, the original content has been removed

2022-04-18

Good

Sorry, the original content has been removed

2022-02-03

Good

2 Biotech Stocks That Could Make You Richer

2021-08-09

check

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4089928668743000,"uuid":"4089928668743000","gmtCreate":1626828501245,"gmtModify":1629511755652,"name":"TTS Sam","pinyin":"ttssamttssam","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":365,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"80.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9914721262,"gmtCreate":1665369283557,"gmtModify":1676537593629,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9914721262","repostId":"9914484075","repostType":1,"repost":{"id":9914484075,"gmtCreate":1665357653098,"gmtModify":1676537589922,"author":{"id":"3583230105554843","authorId":"3583230105554843","name":"Keeley","avatar":"https://community-static.tradeup.com/news/425dded61ea0f1ec6aa9c19997bc9677","crmLevel":5,"crmLevelSwitch":0},"themes":[],"title":"Stocks Technical Analysis #AMC #MSFT #AAPL","htmlText":"Find out more about me here (YouTube/Instagram/Telegram): https://www.linktr.ee/keeleytan If you find my post helpful, I’ll be grateful and appreciate it if you could leave me a like on this post, and follow me for future posts like this. If you have any comments/feedback, feel free to use the link above to Google form. Free signal service on discord is officially up. If interested, head to my discord to check it out! <a target=\"_blank\" href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>&nbsp; Price is playing out as analyzed last week. I'm expecting price to go lower to take the lows at 5.96 after mitigating the current POI at 6.59, no changes to my previous expectations. https://www.tradingview.com/chart/AMC/EYUzXC3b-AMC-Analysis/","listText":"Find out more about me here (YouTube/Instagram/Telegram): https://www.linktr.ee/keeleytan If you find my post helpful, I’ll be grateful and appreciate it if you could leave me a like on this post, and follow me for future posts like this. If you have any comments/feedback, feel free to use the link above to Google form. Free signal service on discord is officially up. If interested, head to my discord to check it out! <a target=\"_blank\" href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>&nbsp; Price is playing out as analyzed last week. I'm expecting price to go lower to take the lows at 5.96 after mitigating the current POI at 6.59, no changes to my previous expectations. https://www.tradingview.com/chart/AMC/EYUzXC3b-AMC-Analysis/","text":"Find out more about me here (YouTube/Instagram/Telegram): https://www.linktr.ee/keeleytan If you find my post helpful, I’ll be grateful and appreciate it if you could leave me a like on this post, and follow me for future posts like this. If you have any comments/feedback, feel free to use the link above to Google form. Free signal service on discord is officially up. If interested, head to my discord to check it out! $AMC Entertainment(AMC)$ Price is playing out as analyzed last week. I'm expecting price to go lower to take the lows at 5.96 after mitigating the current POI at 6.59, no changes to my previous expectations. https://www.tradingview.com/chart/AMC/EYUzXC3b-AMC-Analysis/","images":[{"img":"https://community-static.tradeup.com/news/87c82ac8ffdef891beacca2139e81437"},{"img":"https://community-static.tradeup.com/news/d3b45cfb4b54769e37227ef989830730"},{"img":"https://community-static.tradeup.com/news/c3e5f47bb3d34b2d086b7d2a38936bd9"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9914484075","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9079935043,"gmtCreate":1657145182182,"gmtModify":1676535955360,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9079935043","repostId":"1161524120","repostType":4,"repost":{"id":"1161524120","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1657117821,"share":"https://www.laohu8.com/m/news/1161524120?lang=&edition=full","pubTime":"2022-07-06 22:30","market":"us","language":"en","title":"Oil Extends Its Decline, With Brent Crude Dropping Below $100 a Barrel","url":"https://stock-news.laohu8.com/highlight/detail?id=1161524120","media":"Tiger Newspress","summary":"Oil dropped below $100 a barrel, with Goldman Sachs Group Inc. saying that a plunge driven by fears ","content":"<html><head></head><body><p>Oil dropped below $100 a barrel, with Goldman Sachs Group Inc. saying that a plunge driven by fears a recession will hurt demand was overdone.</p><p>West Texas Intermediate fell as much as 3.59% to trade around $95.96 a barrel. Brent crude fell 3.12% to trade around 99.65 on Tuesday a barrel, its third-largest ever in dollar terms. Meanwhile, Citigroup Inc.’s Ed Morse said the outlook for oil demand will likely see further downward revisions amid higher fuel prices.</p><p>While that drop was borne out of concern of a global recession and technical selling, there’s been little change to market fundamentals. Nearby Brent futures are trading at a giant premium to later months -- indicating market strength -- while disruption to global oil production has been mounting, amid a risk to Kazkahstan’s oil exports.</p><p>“While the odds of a recession are indeed rising, it is premature for the oil market to be succumbing to such concerns,” Goldman Sachs analysts including Damien Courvalin said in a note. “The global economy is still growing, with the rise in oil demand this year set to significantly outperform GDP growth.”</p><p>Oil has opened the third quarter on volatile footing. With central banks including the Federal Reserve hiking interest rates to tame inflation, investors have been pricing in the consequences of a slowdown, even as physical crude markets continue to show signs of vigor and the war in Ukraine drags on.</p><p>A strengthening dollar has also been a headwind for commodities this week, as a gauge of the US currency rallied to the highest level in more than two years, with investors shying away from risk. A rising dollar makes raw materials like oil more expensive for holders of other currencies.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Extends Its Decline, With Brent Crude Dropping Below $100 a Barrel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Extends Its Decline, With Brent Crude Dropping Below $100 a Barrel\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-07-06 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Oil dropped below $100 a barrel, with Goldman Sachs Group Inc. saying that a plunge driven by fears a recession will hurt demand was overdone.</p><p>West Texas Intermediate fell as much as 3.59% to trade around $95.96 a barrel. Brent crude fell 3.12% to trade around 99.65 on Tuesday a barrel, its third-largest ever in dollar terms. Meanwhile, Citigroup Inc.’s Ed Morse said the outlook for oil demand will likely see further downward revisions amid higher fuel prices.</p><p>While that drop was borne out of concern of a global recession and technical selling, there’s been little change to market fundamentals. Nearby Brent futures are trading at a giant premium to later months -- indicating market strength -- while disruption to global oil production has been mounting, amid a risk to Kazkahstan’s oil exports.</p><p>“While the odds of a recession are indeed rising, it is premature for the oil market to be succumbing to such concerns,” Goldman Sachs analysts including Damien Courvalin said in a note. “The global economy is still growing, with the rise in oil demand this year set to significantly outperform GDP growth.”</p><p>Oil has opened the third quarter on volatile footing. With central banks including the Federal Reserve hiking interest rates to tame inflation, investors have been pricing in the consequences of a slowdown, even as physical crude markets continue to show signs of vigor and the war in Ukraine drags on.</p><p>A strengthening dollar has also been a headwind for commodities this week, as a gauge of the US currency rallied to the highest level in more than two years, with investors shying away from risk. A rising dollar makes raw materials like oil more expensive for holders of other currencies.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161524120","content_text":"Oil dropped below $100 a barrel, with Goldman Sachs Group Inc. saying that a plunge driven by fears a recession will hurt demand was overdone.West Texas Intermediate fell as much as 3.59% to trade around $95.96 a barrel. Brent crude fell 3.12% to trade around 99.65 on Tuesday a barrel, its third-largest ever in dollar terms. Meanwhile, Citigroup Inc.’s Ed Morse said the outlook for oil demand will likely see further downward revisions amid higher fuel prices.While that drop was borne out of concern of a global recession and technical selling, there’s been little change to market fundamentals. Nearby Brent futures are trading at a giant premium to later months -- indicating market strength -- while disruption to global oil production has been mounting, amid a risk to Kazkahstan’s oil exports.“While the odds of a recession are indeed rising, it is premature for the oil market to be succumbing to such concerns,” Goldman Sachs analysts including Damien Courvalin said in a note. “The global economy is still growing, with the rise in oil demand this year set to significantly outperform GDP growth.”Oil has opened the third quarter on volatile footing. With central banks including the Federal Reserve hiking interest rates to tame inflation, investors have been pricing in the consequences of a slowdown, even as physical crude markets continue to show signs of vigor and the war in Ukraine drags on.A strengthening dollar has also been a headwind for commodities this week, as a gauge of the US currency rallied to the highest level in more than two years, with investors shying away from risk. A rising dollar makes raw materials like oil more expensive for holders of other currencies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9068375524,"gmtCreate":1651726182341,"gmtModify":1676534957741,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068375524","repostId":"2232025659","repostType":4,"repost":{"id":"2232025659","pubTimestamp":1651712452,"share":"https://www.laohu8.com/m/news/2232025659?lang=&edition=full","pubTime":"2022-05-05 09:00","market":"us","language":"en","title":"Nasdaq Bear Market: 3 Growth Stocks Down 64% (or More) Just Begging to Be Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2232025659","media":"Motley Fool","summary":"These beaten-down stocks are screaming buys following a peak decline of 23% in the Nasdaq.","content":"<html><head></head><body><p>Whether you&#39;re a new or tenured investor, the stock market has sent a clear message over the past four months that corrections are an inevitable part of the investing cycle.</p><p>Since the year began, the benchmark <b>S&amp;P 500</b> and iconic <b>Dow Jones Industrial Average</b> entered correction territory with respective declines of at least 10%. Things have been even worse for the growth-driven <b>Nasdaq Composite</b>, which has shed 23% since hitting its all-time closing high in November. This officially puts the Nasdaq in its first bear market since the pandemic meltdown in March 2020.</p><p>Although big declines in the major indexes can be scary at times, history has shown that they&#39;re the perfect time to put your money to work. Every major index, including the Nasdaq Composite, eventually shrugs off each and every correction.</p><p>What&#39;s more, growth stocks can be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest places to invest your money during a correction or bear market. A <b>Bank of America</b>/Merrill Lynch report that examined the performance of growth stocks and value stocks over 90 years (1926-2015) found that growth stocks outperformed during recessions and periods of economic weakness.</p><p>The following three growth stocks are at least 64% below their all-time highs and are now begging to be bought at reduced levels.</p><h2>Sea Limited: Down 78% from its all-time high</h2><p>The first growth stock that&#39;s taken an absolute beating as the Nasdaq has swooned is Singapore-based conglomerate <b>Sea Limited</b>. Shares of Sea skyrocketed tenfold in just an 18-month period during the pandemic, but have gone on to lose 78% of their value since peaking in October.</p><p>Sea is facing a number of pressing questions as global inflation heats up and COVID-19 continues to wreak havoc on supply chains, especially in Asian markets. In particular, Wall Street had become accustomed to jaw-dropping sales growth over the past couple of years. Looking ahead, Sea&#39;s revenue growth is slated to slow a bit, with annual losses expected to continue for a few more years. When big market declines occur, valuation comes into focus, and companies with large annual losses, like Sea Limited, often take it on the chin.</p><p>But there&#39;s another side to this story that should excite patient growth investors. Specifically, Sea has three rapidly growing segments that can all become serious cash flow generators.</p><p>For the moment, the company&#39;s gaming division, known as Garena, is the only operating segment bringing in positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Hit mobile game <i>Free Fire</i> helped lift the number of quarterly active users (QAUs) to 654 million as of the end of 2021. More importantly, 11.8% of these QAUs were paying to play Sea&#39;s games. The typical pay-to-play conversion ratio in mobile gaming is in the low single digits.</p><p>There&#39;s also excitement for SeaMoney, the company&#39;s digital financial services segment. Although it&#39;s still relatively new, nearly 46 million QAUs were using SeaMoney products and services, such as digital wallets, in the fourth quarter. This is an intriguing segment considering that Sea operates in a number of emerging regions where access to basic banking services can be limited.</p><p>Lastly, there&#39;s e-commerce platform Shopee, which has consistently been the most downloaded shopping app in Southeast Asia. Shopee has been picking up momentum in Brazil, too. During the fourth quarter, Shopee had $18.2 billion in gross merchandise value (GMV) traverse its network. That&#39;s more than the $10 billion in GMV recognized in all of 2018. If Sea can significantly improve e-commerce EBITDA into 2023, its share price could rebound in a big way.</p><h2>Green Thumb Industries: Down 64% from its all-time high</h2><p>A second growth stock that&#39;s been absolutely pulverized and is now begging to be bought is cannabis multi-state operator (MSO) <b>Green Thumb Industries</b>. Shares of Green Thumb have declined by 64% since hitting their intra-day high a little over a year ago.</p><p>During the first quarter of 2021, marijuana stocks were all the rage. A Democrat-led Congress, coupled with President Joe Biden taking office, made it appear likely that federal legalization, or at the very least cannabis banking reform, would become a reality. However, with COVID-19 and geopolitical issues dominating lawmakers&#39; time, no reforms have been passed on Capitol Hill. As a result, pot stocks like Green Thumb have been taken to the woodshed.</p><p>But despite a lack of federal reforms, we&#39;ve still witnessed three-quarters of all states legalize cannabis in some capacity. To add, 18 of these states have green-lit adult-use recreational consumption. The point is that individual state regulation is providing more than enough opportunity for well-funded MSOs to thrive.</p><p>Green Thumb opened its 77th operating dispensary last month and generated retail sales from 14 states in 2021.  Although it does have a presence in high-dollar markets like California, the company has wisely chosen to enter a number of limited-license markets. These are states that purposely limit how many cannabis dispensary licenses are issued in total, as well as to a single business. It&#39;s a way of promoting competition and ensuring that companies like Green Thumb have a fair shot to build up their brand(s) and garner a following.</p><p>The one factor that really makes Green Thumb special is its product mix. Only around a third of the company&#39;s sales are derived from dried flower.  The remainder comes from vape products, infused beverages, pre-rolls, edibles, and other derivatives. The key here is that derivatives sport higher price points <i>and</i> better margins. These higher margins have allowed Green Thumb to generate recurring profits while most other MSOs are still losing money.</p><p>Considering that Green Thumb Industries is expected to continue growing its sales by 20% to 25% annually, its forward-year price-to-earnings ratio of 24 makes it a bargain.</p><h2>Etsy: Down 70% from its all-time high</h2><p>A third and final growth stock that&#39;s been battered by the Nasdaq bear market decline is specialty online retail platform <b>Etsy</b>. The former pandemic superstar has shed 70% of its value since hitting an all-time intra-day high five months ago.</p><p>The biggest concerns for Etsy are historically high inflation and the growing prospect of a recession in the United States. The cost for virtually everything has soared, which threatens to reduce consumer spending. That would be bad news for Etsy, which relies on merchants to boost their ad spending over time.</p><p>On the other hand, trying to time inevitable recessions in the U.S. economy is a fool&#39;s errand. History has shown that most recessions only last a few months or a couple of quarters. By comparison, periods of economic expansion are measured in years. Buying rapidly growing and innovative e-commerce players during periods of weakness and holding for years is probably going to be a smart move.</p><p>Furthermore, Etsy brings a competitive advantage to the table that should allow it to stand out. Whereas most online retail platforms target volume, Etsy&#39;s merchants are usually smaller businesses that offer unique/customized products and services that enhance consumer engagement. There&#39;s not an online retail platform that offers engagement at scale quite like Etsy.</p><p>Something else to excite long-term investors is Etsy&#39;s success in converting casual shoppers into habitual buyers. A habitual buyer is defined as a shopper who makes at least six purchases over a trailing-12-month period, with the aggregate value of those purchases hitting at least $200. Since the beginning of the pandemic, the number of habitual buyers has grown by 224%! These habitual buyers are the company&#39;s key to extracting more ad revenue out of the merchants on its platform.</p><p>Even if the U.S. enters a recession -- U.S. first-quarter gross domestic product declined by 1.4% -- Etsy is well-positioned to deliver sustainable double-digit sales growth. Based on Wall Street&#39;s consensus profit forecast (which has proved fluid in recent weeks), a share of Etsy can be picked up for just 21 times forecast earnings in 2023. That&#39;s as inexpensive as this company has ever been.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Bear Market: 3 Growth Stocks Down 64% (or More) Just Begging to Be Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Bear Market: 3 Growth Stocks Down 64% (or More) Just Begging to Be Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-05 09:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/04/nasdaq-bear-market-3-growth-stocks-down-64-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Whether you're a new or tenured investor, the stock market has sent a clear message over the past four months that corrections are an inevitable part of the investing cycle.Since the year began, the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/04/nasdaq-bear-market-3-growth-stocks-down-64-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd","GTBIF":"Green Thumb Industries Inc.","ETSY":"Etsy, Inc."},"source_url":"https://www.fool.com/investing/2022/05/04/nasdaq-bear-market-3-growth-stocks-down-64-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2232025659","content_text":"Whether you're a new or tenured investor, the stock market has sent a clear message over the past four months that corrections are an inevitable part of the investing cycle.Since the year began, the benchmark S&P 500 and iconic Dow Jones Industrial Average entered correction territory with respective declines of at least 10%. Things have been even worse for the growth-driven Nasdaq Composite, which has shed 23% since hitting its all-time closing high in November. This officially puts the Nasdaq in its first bear market since the pandemic meltdown in March 2020.Although big declines in the major indexes can be scary at times, history has shown that they're the perfect time to put your money to work. Every major index, including the Nasdaq Composite, eventually shrugs off each and every correction.What's more, growth stocks can be one of the smartest places to invest your money during a correction or bear market. A Bank of America/Merrill Lynch report that examined the performance of growth stocks and value stocks over 90 years (1926-2015) found that growth stocks outperformed during recessions and periods of economic weakness.The following three growth stocks are at least 64% below their all-time highs and are now begging to be bought at reduced levels.Sea Limited: Down 78% from its all-time highThe first growth stock that's taken an absolute beating as the Nasdaq has swooned is Singapore-based conglomerate Sea Limited. Shares of Sea skyrocketed tenfold in just an 18-month period during the pandemic, but have gone on to lose 78% of their value since peaking in October.Sea is facing a number of pressing questions as global inflation heats up and COVID-19 continues to wreak havoc on supply chains, especially in Asian markets. In particular, Wall Street had become accustomed to jaw-dropping sales growth over the past couple of years. Looking ahead, Sea's revenue growth is slated to slow a bit, with annual losses expected to continue for a few more years. When big market declines occur, valuation comes into focus, and companies with large annual losses, like Sea Limited, often take it on the chin.But there's another side to this story that should excite patient growth investors. Specifically, Sea has three rapidly growing segments that can all become serious cash flow generators.For the moment, the company's gaming division, known as Garena, is the only operating segment bringing in positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Hit mobile game Free Fire helped lift the number of quarterly active users (QAUs) to 654 million as of the end of 2021. More importantly, 11.8% of these QAUs were paying to play Sea's games. The typical pay-to-play conversion ratio in mobile gaming is in the low single digits.There's also excitement for SeaMoney, the company's digital financial services segment. Although it's still relatively new, nearly 46 million QAUs were using SeaMoney products and services, such as digital wallets, in the fourth quarter. This is an intriguing segment considering that Sea operates in a number of emerging regions where access to basic banking services can be limited.Lastly, there's e-commerce platform Shopee, which has consistently been the most downloaded shopping app in Southeast Asia. Shopee has been picking up momentum in Brazil, too. During the fourth quarter, Shopee had $18.2 billion in gross merchandise value (GMV) traverse its network. That's more than the $10 billion in GMV recognized in all of 2018. If Sea can significantly improve e-commerce EBITDA into 2023, its share price could rebound in a big way.Green Thumb Industries: Down 64% from its all-time highA second growth stock that's been absolutely pulverized and is now begging to be bought is cannabis multi-state operator (MSO) Green Thumb Industries. Shares of Green Thumb have declined by 64% since hitting their intra-day high a little over a year ago.During the first quarter of 2021, marijuana stocks were all the rage. A Democrat-led Congress, coupled with President Joe Biden taking office, made it appear likely that federal legalization, or at the very least cannabis banking reform, would become a reality. However, with COVID-19 and geopolitical issues dominating lawmakers' time, no reforms have been passed on Capitol Hill. As a result, pot stocks like Green Thumb have been taken to the woodshed.But despite a lack of federal reforms, we've still witnessed three-quarters of all states legalize cannabis in some capacity. To add, 18 of these states have green-lit adult-use recreational consumption. The point is that individual state regulation is providing more than enough opportunity for well-funded MSOs to thrive.Green Thumb opened its 77th operating dispensary last month and generated retail sales from 14 states in 2021.  Although it does have a presence in high-dollar markets like California, the company has wisely chosen to enter a number of limited-license markets. These are states that purposely limit how many cannabis dispensary licenses are issued in total, as well as to a single business. It's a way of promoting competition and ensuring that companies like Green Thumb have a fair shot to build up their brand(s) and garner a following.The one factor that really makes Green Thumb special is its product mix. Only around a third of the company's sales are derived from dried flower.  The remainder comes from vape products, infused beverages, pre-rolls, edibles, and other derivatives. The key here is that derivatives sport higher price points and better margins. These higher margins have allowed Green Thumb to generate recurring profits while most other MSOs are still losing money.Considering that Green Thumb Industries is expected to continue growing its sales by 20% to 25% annually, its forward-year price-to-earnings ratio of 24 makes it a bargain.Etsy: Down 70% from its all-time highA third and final growth stock that's been battered by the Nasdaq bear market decline is specialty online retail platform Etsy. The former pandemic superstar has shed 70% of its value since hitting an all-time intra-day high five months ago.The biggest concerns for Etsy are historically high inflation and the growing prospect of a recession in the United States. The cost for virtually everything has soared, which threatens to reduce consumer spending. That would be bad news for Etsy, which relies on merchants to boost their ad spending over time.On the other hand, trying to time inevitable recessions in the U.S. economy is a fool's errand. History has shown that most recessions only last a few months or a couple of quarters. By comparison, periods of economic expansion are measured in years. Buying rapidly growing and innovative e-commerce players during periods of weakness and holding for years is probably going to be a smart move.Furthermore, Etsy brings a competitive advantage to the table that should allow it to stand out. Whereas most online retail platforms target volume, Etsy's merchants are usually smaller businesses that offer unique/customized products and services that enhance consumer engagement. There's not an online retail platform that offers engagement at scale quite like Etsy.Something else to excite long-term investors is Etsy's success in converting casual shoppers into habitual buyers. A habitual buyer is defined as a shopper who makes at least six purchases over a trailing-12-month period, with the aggregate value of those purchases hitting at least $200. Since the beginning of the pandemic, the number of habitual buyers has grown by 224%! These habitual buyers are the company's key to extracting more ad revenue out of the merchants on its platform.Even if the U.S. enters a recession -- U.S. first-quarter gross domestic product declined by 1.4% -- Etsy is well-positioned to deliver sustainable double-digit sales growth. Based on Wall Street's consensus profit forecast (which has proved fluid in recent weeks), a share of Etsy can be picked up for just 21 times forecast earnings in 2023. That's as inexpensive as this company has ever been.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9060774977,"gmtCreate":1651198003722,"gmtModify":1676534869215,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060774977","repostId":"1139170651","repostType":4,"repost":{"id":"1139170651","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1651193364,"share":"https://www.laohu8.com/m/news/1139170651?lang=&edition=full","pubTime":"2022-04-29 08:49","market":"sg","language":"en","title":"Singapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit","url":"https://stock-news.laohu8.com/highlight/detail?id=1139170651","media":"Tiger Newspress","summary":"THE following companies saw new developments that may affect trading of their securities on Friday (","content":"<html><head></head><body><p>THE following companies saw new developments that may affect trading of their securities on Friday (April 29):</p><p>Singapore’s largest bank <a href=\"https://laohu8.com/S/D05.SI\">DBS</a> reported a net profit of S$1.8 billion for the first quarter ended Mar 31, 2022, down 10 per cent from the record S$2.1 billion posted a year ago.</p><p>This was in line with a S$1.88 billion consensus estimate from analysts polled by Bloomberg.</p><p>In a trading update on Friday (Apr 29), the bank attributed its weaker earnings to a high base for wealth management and treasury markets activities a year ago, when “buoyant market sentiment and clear market momentum had driven income from both activities to exceptional levels”.</p><p><a href=\"https://laohu8.com/S/O39.SI\">OCBC</a> reported S$1.36 billion in net profit for the quarter to March, 10 per cent lower than the record earnings of S$1.5 billion a year ago, as the local bank&#39;s wealth management fees, trading income and life insurance profit slipped.</p><p>The poorer showing from wealth management fees and trading income - expected by analysts - was announced in the bank&#39;s financial results released in pre-trading hours on Friday (Apr 29) for the first quarter of FY2022.</p><p><a href=\"https://laohu8.com/S/U11.SI\">UOB</a> reported on Friday (Apr 29) that Q1 net profit fell 10 per cent on year to S$906 million, as total income was impacted by market volatility.</p><p>Its net profit for the 3 months ended Mar 31, 2022 was also 11 per cent lower quarter on quarter, and fell short of the S$1.037 billion average estimate from 5 analysts polled by Bloomberg.</p><p>Total income for the first quarter fell 5 per cent on year to S$2.4 billion, dragged by lower net fee income and other non-interest income.</p><p>CUSCADEN Peak will offer to acquire <a href=\"https://laohu8.com/S/SK6U.SI\">SPH Reit</a> at S$0.9372 per unit, which is the minimum offer price required after adjusting for recent SPH Reit distributions.</p><p>The offer price is 3.9 per cent below SPH Reit&#39;s last traded price, on Thursday (Apr 28), of S$0.975. It is also 2.8 per cent below SPH Reit&#39;s daily volume-weighted average price (VWAP) over the last month.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-29 08:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>THE following companies saw new developments that may affect trading of their securities on Friday (April 29):</p><p>Singapore’s largest bank <a href=\"https://laohu8.com/S/D05.SI\">DBS</a> reported a net profit of S$1.8 billion for the first quarter ended Mar 31, 2022, down 10 per cent from the record S$2.1 billion posted a year ago.</p><p>This was in line with a S$1.88 billion consensus estimate from analysts polled by Bloomberg.</p><p>In a trading update on Friday (Apr 29), the bank attributed its weaker earnings to a high base for wealth management and treasury markets activities a year ago, when “buoyant market sentiment and clear market momentum had driven income from both activities to exceptional levels”.</p><p><a href=\"https://laohu8.com/S/O39.SI\">OCBC</a> reported S$1.36 billion in net profit for the quarter to March, 10 per cent lower than the record earnings of S$1.5 billion a year ago, as the local bank&#39;s wealth management fees, trading income and life insurance profit slipped.</p><p>The poorer showing from wealth management fees and trading income - expected by analysts - was announced in the bank&#39;s financial results released in pre-trading hours on Friday (Apr 29) for the first quarter of FY2022.</p><p><a href=\"https://laohu8.com/S/U11.SI\">UOB</a> reported on Friday (Apr 29) that Q1 net profit fell 10 per cent on year to S$906 million, as total income was impacted by market volatility.</p><p>Its net profit for the 3 months ended Mar 31, 2022 was also 11 per cent lower quarter on quarter, and fell short of the S$1.037 billion average estimate from 5 analysts polled by Bloomberg.</p><p>Total income for the first quarter fell 5 per cent on year to S$2.4 billion, dragged by lower net fee income and other non-interest income.</p><p>CUSCADEN Peak will offer to acquire <a href=\"https://laohu8.com/S/SK6U.SI\">SPH Reit</a> at S$0.9372 per unit, which is the minimum offer price required after adjusting for recent SPH Reit distributions.</p><p>The offer price is 3.9 per cent below SPH Reit&#39;s last traded price, on Thursday (Apr 28), of S$0.975. It is also 2.8 per cent below SPH Reit&#39;s daily volume-weighted average price (VWAP) over the last month.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SK6U.SI":"百利宫房地产投资信托","O39.SI":"华侨银行","D05.SI":"星展集团控股","U11.SI":"大华银行"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139170651","content_text":"THE following companies saw new developments that may affect trading of their securities on Friday (April 29):Singapore’s largest bank DBS reported a net profit of S$1.8 billion for the first quarter ended Mar 31, 2022, down 10 per cent from the record S$2.1 billion posted a year ago.This was in line with a S$1.88 billion consensus estimate from analysts polled by Bloomberg.In a trading update on Friday (Apr 29), the bank attributed its weaker earnings to a high base for wealth management and treasury markets activities a year ago, when “buoyant market sentiment and clear market momentum had driven income from both activities to exceptional levels”.OCBC reported S$1.36 billion in net profit for the quarter to March, 10 per cent lower than the record earnings of S$1.5 billion a year ago, as the local bank's wealth management fees, trading income and life insurance profit slipped.The poorer showing from wealth management fees and trading income - expected by analysts - was announced in the bank's financial results released in pre-trading hours on Friday (Apr 29) for the first quarter of FY2022.UOB reported on Friday (Apr 29) that Q1 net profit fell 10 per cent on year to S$906 million, as total income was impacted by market volatility.Its net profit for the 3 months ended Mar 31, 2022 was also 11 per cent lower quarter on quarter, and fell short of the S$1.037 billion average estimate from 5 analysts polled by Bloomberg.Total income for the first quarter fell 5 per cent on year to S$2.4 billion, dragged by lower net fee income and other non-interest income.CUSCADEN Peak will offer to acquire SPH Reit at S$0.9372 per unit, which is the minimum offer price required after adjusting for recent SPH Reit distributions.The offer price is 3.9 per cent below SPH Reit's last traded price, on Thursday (Apr 28), of S$0.975. It is also 2.8 per cent below SPH Reit's daily volume-weighted average price (VWAP) over the last month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9084026396,"gmtCreate":1650779924396,"gmtModify":1676534792116,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9084026396","repostId":"1180044728","repostType":4,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081497610,"gmtCreate":1650262073244,"gmtModify":1676534681757,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081497610","repostId":"9081196317","repostType":1,"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091295003,"gmtCreate":1643865343186,"gmtModify":1676533865744,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091295003","repostId":"1196109622","repostType":4,"repost":{"id":"1196109622","pubTimestamp":1643852105,"share":"https://www.laohu8.com/m/news/1196109622?lang=&edition=full","pubTime":"2022-02-03 09:35","market":"us","language":"en","title":"2 Biotech Stocks That Could Make You Richer","url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","media":"Motley Fool","summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","content":"<html><head></head><body><p>Investing in the stock market won&#39;t make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.</p><p>Let&#39;s address the second part of this strategy: picking the right stocks, which isn&#39;t always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a> and <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a>. Here&#39;s why.</p><p>1. <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a></p><p>To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.</p><p>On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.</p><p>However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called<b>2Seventy Bio</b>.</p><p>Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.</p><p>There are few treatments for TDT. But Bluebird&#39;s version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.</p><p>The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).</p><p>ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.</p><p>Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.</p><p>However, Bluebird&#39;s current market cap is barely over $500 million. The market isn&#39;t putting much value in the company&#39;s programs at all. That&#39;s what makes this biotech a potentially attractive option. If the company&#39;s master plan actualizes, its shares could skyrocket.</p><p>2. <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a></p><p>Exelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company&#39;s sales. But thebiotech&#39;s reliance on its crown jewel doesn&#39;t bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.</p><p>Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.</p><p>First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it&#39;s estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it&#39;s predicting $1.3 billion to $1.4 billion in revenue.</p><p>Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That&#39;s good news for Exelixis and its shareholders.</p><p>The biotech is now looking to replicate the success it&#39;s had with Cabometyx. It&#39;s advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.</p><p>Within the next couple of years, these products should be moving into late-stage studies. Exelixis&#39; forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLUE":"bluebird bio Inc.","EXEL":"伊克力西斯"},"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196109622","content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898268088,"gmtCreate":1628501719344,"gmtModify":1703507161164,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"check","listText":"check","text":"check","images":[{"img":"https://static.tigerbbs.com/65c3b9482b42ce2e2c8b12bb2a4e0b53","width":"1080","height":"2265"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898268088","isVote":1,"tweetType":1,"viewCount":580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0}],"hots":[{"id":9091295003,"gmtCreate":1643865343186,"gmtModify":1676533865744,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091295003","repostId":"1196109622","repostType":4,"repost":{"id":"1196109622","pubTimestamp":1643852105,"share":"https://www.laohu8.com/m/news/1196109622?lang=&edition=full","pubTime":"2022-02-03 09:35","market":"us","language":"en","title":"2 Biotech Stocks That Could Make You Richer","url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","media":"Motley Fool","summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","content":"<html><head></head><body><p>Investing in the stock market won&#39;t make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.</p><p>Let&#39;s address the second part of this strategy: picking the right stocks, which isn&#39;t always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a> and <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a>. Here&#39;s why.</p><p>1. <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a></p><p>To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.</p><p>On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.</p><p>However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called<b>2Seventy Bio</b>.</p><p>Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.</p><p>There are few treatments for TDT. But Bluebird&#39;s version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.</p><p>The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).</p><p>ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.</p><p>Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.</p><p>However, Bluebird&#39;s current market cap is barely over $500 million. The market isn&#39;t putting much value in the company&#39;s programs at all. That&#39;s what makes this biotech a potentially attractive option. If the company&#39;s master plan actualizes, its shares could skyrocket.</p><p>2. <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a></p><p>Exelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company&#39;s sales. But thebiotech&#39;s reliance on its crown jewel doesn&#39;t bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.</p><p>Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.</p><p>First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it&#39;s estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it&#39;s predicting $1.3 billion to $1.4 billion in revenue.</p><p>Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That&#39;s good news for Exelixis and its shareholders.</p><p>The biotech is now looking to replicate the success it&#39;s had with Cabometyx. It&#39;s advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.</p><p>Within the next couple of years, these products should be moving into late-stage studies. Exelixis&#39; forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLUE":"bluebird bio Inc.","EXEL":"伊克力西斯"},"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196109622","content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9060774977,"gmtCreate":1651198003722,"gmtModify":1676534869215,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9060774977","repostId":"1139170651","repostType":4,"repost":{"id":"1139170651","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1651193364,"share":"https://www.laohu8.com/m/news/1139170651?lang=&edition=full","pubTime":"2022-04-29 08:49","market":"sg","language":"en","title":"Singapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit","url":"https://stock-news.laohu8.com/highlight/detail?id=1139170651","media":"Tiger Newspress","summary":"THE following companies saw new developments that may affect trading of their securities on Friday (","content":"<html><head></head><body><p>THE following companies saw new developments that may affect trading of their securities on Friday (April 29):</p><p>Singapore’s largest bank <a href=\"https://laohu8.com/S/D05.SI\">DBS</a> reported a net profit of S$1.8 billion for the first quarter ended Mar 31, 2022, down 10 per cent from the record S$2.1 billion posted a year ago.</p><p>This was in line with a S$1.88 billion consensus estimate from analysts polled by Bloomberg.</p><p>In a trading update on Friday (Apr 29), the bank attributed its weaker earnings to a high base for wealth management and treasury markets activities a year ago, when “buoyant market sentiment and clear market momentum had driven income from both activities to exceptional levels”.</p><p><a href=\"https://laohu8.com/S/O39.SI\">OCBC</a> reported S$1.36 billion in net profit for the quarter to March, 10 per cent lower than the record earnings of S$1.5 billion a year ago, as the local bank&#39;s wealth management fees, trading income and life insurance profit slipped.</p><p>The poorer showing from wealth management fees and trading income - expected by analysts - was announced in the bank&#39;s financial results released in pre-trading hours on Friday (Apr 29) for the first quarter of FY2022.</p><p><a href=\"https://laohu8.com/S/U11.SI\">UOB</a> reported on Friday (Apr 29) that Q1 net profit fell 10 per cent on year to S$906 million, as total income was impacted by market volatility.</p><p>Its net profit for the 3 months ended Mar 31, 2022 was also 11 per cent lower quarter on quarter, and fell short of the S$1.037 billion average estimate from 5 analysts polled by Bloomberg.</p><p>Total income for the first quarter fell 5 per cent on year to S$2.4 billion, dragged by lower net fee income and other non-interest income.</p><p>CUSCADEN Peak will offer to acquire <a href=\"https://laohu8.com/S/SK6U.SI\">SPH Reit</a> at S$0.9372 per unit, which is the minimum offer price required after adjusting for recent SPH Reit distributions.</p><p>The offer price is 3.9 per cent below SPH Reit&#39;s last traded price, on Thursday (Apr 28), of S$0.975. It is also 2.8 per cent below SPH Reit&#39;s daily volume-weighted average price (VWAP) over the last month.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stocks To Watch: DBS, OCBC, UOB and SPH Reit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-29 08:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>THE following companies saw new developments that may affect trading of their securities on Friday (April 29):</p><p>Singapore’s largest bank <a href=\"https://laohu8.com/S/D05.SI\">DBS</a> reported a net profit of S$1.8 billion for the first quarter ended Mar 31, 2022, down 10 per cent from the record S$2.1 billion posted a year ago.</p><p>This was in line with a S$1.88 billion consensus estimate from analysts polled by Bloomberg.</p><p>In a trading update on Friday (Apr 29), the bank attributed its weaker earnings to a high base for wealth management and treasury markets activities a year ago, when “buoyant market sentiment and clear market momentum had driven income from both activities to exceptional levels”.</p><p><a href=\"https://laohu8.com/S/O39.SI\">OCBC</a> reported S$1.36 billion in net profit for the quarter to March, 10 per cent lower than the record earnings of S$1.5 billion a year ago, as the local bank&#39;s wealth management fees, trading income and life insurance profit slipped.</p><p>The poorer showing from wealth management fees and trading income - expected by analysts - was announced in the bank&#39;s financial results released in pre-trading hours on Friday (Apr 29) for the first quarter of FY2022.</p><p><a href=\"https://laohu8.com/S/U11.SI\">UOB</a> reported on Friday (Apr 29) that Q1 net profit fell 10 per cent on year to S$906 million, as total income was impacted by market volatility.</p><p>Its net profit for the 3 months ended Mar 31, 2022 was also 11 per cent lower quarter on quarter, and fell short of the S$1.037 billion average estimate from 5 analysts polled by Bloomberg.</p><p>Total income for the first quarter fell 5 per cent on year to S$2.4 billion, dragged by lower net fee income and other non-interest income.</p><p>CUSCADEN Peak will offer to acquire <a href=\"https://laohu8.com/S/SK6U.SI\">SPH Reit</a> at S$0.9372 per unit, which is the minimum offer price required after adjusting for recent SPH Reit distributions.</p><p>The offer price is 3.9 per cent below SPH Reit&#39;s last traded price, on Thursday (Apr 28), of S$0.975. It is also 2.8 per cent below SPH Reit&#39;s daily volume-weighted average price (VWAP) over the last month.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SK6U.SI":"百利宫房地产投资信托","O39.SI":"华侨银行","D05.SI":"星展集团控股","U11.SI":"大华银行"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139170651","content_text":"THE following companies saw new developments that may affect trading of their securities on Friday (April 29):Singapore’s largest bank DBS reported a net profit of S$1.8 billion for the first quarter ended Mar 31, 2022, down 10 per cent from the record S$2.1 billion posted a year ago.This was in line with a S$1.88 billion consensus estimate from analysts polled by Bloomberg.In a trading update on Friday (Apr 29), the bank attributed its weaker earnings to a high base for wealth management and treasury markets activities a year ago, when “buoyant market sentiment and clear market momentum had driven income from both activities to exceptional levels”.OCBC reported S$1.36 billion in net profit for the quarter to March, 10 per cent lower than the record earnings of S$1.5 billion a year ago, as the local bank's wealth management fees, trading income and life insurance profit slipped.The poorer showing from wealth management fees and trading income - expected by analysts - was announced in the bank's financial results released in pre-trading hours on Friday (Apr 29) for the first quarter of FY2022.UOB reported on Friday (Apr 29) that Q1 net profit fell 10 per cent on year to S$906 million, as total income was impacted by market volatility.Its net profit for the 3 months ended Mar 31, 2022 was also 11 per cent lower quarter on quarter, and fell short of the S$1.037 billion average estimate from 5 analysts polled by Bloomberg.Total income for the first quarter fell 5 per cent on year to S$2.4 billion, dragged by lower net fee income and other non-interest income.CUSCADEN Peak will offer to acquire SPH Reit at S$0.9372 per unit, which is the minimum offer price required after adjusting for recent SPH Reit distributions.The offer price is 3.9 per cent below SPH Reit's last traded price, on Thursday (Apr 28), of S$0.975. It is also 2.8 per cent below SPH Reit's daily volume-weighted average price (VWAP) over the last month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9068375524,"gmtCreate":1651726182341,"gmtModify":1676534957741,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068375524","repostId":"2232025659","repostType":4,"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9084026396,"gmtCreate":1650779924396,"gmtModify":1676534792116,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9084026396","repostId":"1180044728","repostType":4,"repost":{"id":"1180044728","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1650777464,"share":"https://www.laohu8.com/m/news/1180044728?lang=&edition=full","pubTime":"2022-04-24 13:17","market":"us","language":"en","title":"Warren Buffett Turns 91: A Highlight For Each Decade Of His Life","url":"https://stock-news.laohu8.com/highlight/detail?id=1180044728","media":"Benzinga","summary":"Legendary investor Warren Buffett was born Aug. 30, 1930. The “Oracle of Omaha” turns 91 today and h","content":"<html><head></head><body><p><i>Legendary investor</i> <i><b>Warren Buffett</b></i> <i>was born Aug. 30, 1930. The “Oracle of Omaha” turns 91 today and has now lived through 10 decades.</i></p><p><img src=\"https://static.tigerbbs.com/cd569a86b7d1c849ffdd55a3a194a437\" tg-width=\"685\" tg-height=\"375\" width=\"100%\" height=\"auto\"/></p><p><i>Buffett has been one of the greatest investors of the last six decades and remains the active chairman of</i> <i><b>Berkshire Hathaway</b></i> <i>(NYSE:BRK-A)(NYSE:BRK-B). This article will showcase a highlight from each decade of Buffett’s personal and investment career.</i></p><p><b>1930:</b>Warren Buffett was born Aug. 30, 1930. His father Howard was a former stockbroker, which would have a huge influence on Buffett’s decision to get involved with the business.</p><p><b>1940:</b>Buffett purchased his first stock at the age of 11. The purchase was for three shares of Cities Service Preferred, a natural gas company. Buffett bought the shares at $38 only to see them soon drop to $27 each. He waited until they hit $40 to sell for a profit. Shares later hit $200 each, which Buffett has since cited as a lesson on patience in investing.</p><p><b>1950:</b>Despite his growing wealth, Buffett has lived in the same house in Nebraska, Omaha since 1958. The home was purchased for $31,500. Adjusted for inflation, that would be the equivalent of over $280,000 today.</p><p><b>1960:</b>By the year 1965, Buffett had assumed control of textiles company Berkshire Hathaway thanks to acquiring 49%. He became a director of the company and would work on gaining full control and also diversifying the company away from textiles.</p><p><b>1970:</b> Buffett became the author of the annual Berkshire Hathaway letters in the 1970s. These letters are considered must-reads for investors and every year, what Buffett writes to shareholders is analyzed with great detail. The letters include explanations for investments or why items were sold. The letters also include life lessons and memorable quotes from the “Oracle of Omaha.”</p><p><b>1980:</b>In 1988, Buffett started accumulating shares of <b>Coca-Cola</b> for Berkshire Hathaway. After several large purchases, Berkshire Hathaway owned 7% of the company worth $1.02 billion. Buffett has a long history with Coca-Cola, once selling bottles for a penny profit. Berkshire Hathaway still owns 800 million shares of KO, worth nearly $18 billion.</p><p><b>1990:</b>Geico insurance has been one of the biggest pieces for Berkshire Hathaway since it acquired full control in the 1990s. Berkshire acquired the insurance company by buying out the 49% it did not own up until this point.</p><p>Buffett had been an investor of Geico shares dating back to 1951. Benjamin Graham, Buffett’s mentor and professor, was once the chairman of Geico. The insurance company is forever linked to two of the most well-known investors.</p><p><b>2000:</b>The 2000s represented a great period of fortune and giving for Warren Buffett. In 2008, Buffett became the richest man in the world, with Forbes valuing his wealth at $62 billion. Buffett took over the top spot from <b>Microsoft</b> founder Bill Gates, who had held the number one position for thirteen consecutive years. Buffett pledged in 2006 to give away the majority of his wealth after his death, including 85% to the Bill and Melinda Gates Foundation.</p><p><b>2010:</b>Berkshire Hathaway started buying stock in <b>Apple</b> in 2016. Buffett has since admitted he wishes he would have bought shares earlier.</p><p>“It’s probably the best business I know in the world,” Buffett told CNBC. Berkshire bought shares of Apple again throughout the decade to make it one of the biggest pieces of the investment portfolio.</p><p>“I don’t think of Apple as a stock. I think of it as a third business,” Buffett told CNBC referring to Apple being the company’s third-biggest holding behind Geico and railroad interests.</p><p><b>2020:</b>Warren Buffett showed an investor lesson when he sold out of his stake in the big four airlines. A longtime vocal non-supporter of buying airline stocks, he sold his stake worth around $7 billion at a loss.</p><p>He ditched his stakes in <b>American Airlines</b>, <b>Delta Air Lines</b>, <b>Southwest Airlines</b>, and <b>United Airlines</b> believing passenger numbers would not recover after the pandemic. He also cited carriers could be left with too many planes and would be hurt financially due to government loans.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett Turns 91: A Highlight For Each Decade Of His Life</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett Turns 91: A Highlight For Each Decade Of His Life\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-04-24 13:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><i>Legendary investor</i> <i><b>Warren Buffett</b></i> <i>was born Aug. 30, 1930. The “Oracle of Omaha” turns 91 today and has now lived through 10 decades.</i></p><p><img src=\"https://static.tigerbbs.com/cd569a86b7d1c849ffdd55a3a194a437\" tg-width=\"685\" tg-height=\"375\" width=\"100%\" height=\"auto\"/></p><p><i>Buffett has been one of the greatest investors of the last six decades and remains the active chairman of</i> <i><b>Berkshire Hathaway</b></i> <i>(NYSE:BRK-A)(NYSE:BRK-B). This article will showcase a highlight from each decade of Buffett’s personal and investment career.</i></p><p><b>1930:</b>Warren Buffett was born Aug. 30, 1930. His father Howard was a former stockbroker, which would have a huge influence on Buffett’s decision to get involved with the business.</p><p><b>1940:</b>Buffett purchased his first stock at the age of 11. The purchase was for three shares of Cities Service Preferred, a natural gas company. Buffett bought the shares at $38 only to see them soon drop to $27 each. He waited until they hit $40 to sell for a profit. Shares later hit $200 each, which Buffett has since cited as a lesson on patience in investing.</p><p><b>1950:</b>Despite his growing wealth, Buffett has lived in the same house in Nebraska, Omaha since 1958. The home was purchased for $31,500. Adjusted for inflation, that would be the equivalent of over $280,000 today.</p><p><b>1960:</b>By the year 1965, Buffett had assumed control of textiles company Berkshire Hathaway thanks to acquiring 49%. He became a director of the company and would work on gaining full control and also diversifying the company away from textiles.</p><p><b>1970:</b> Buffett became the author of the annual Berkshire Hathaway letters in the 1970s. These letters are considered must-reads for investors and every year, what Buffett writes to shareholders is analyzed with great detail. The letters include explanations for investments or why items were sold. The letters also include life lessons and memorable quotes from the “Oracle of Omaha.”</p><p><b>1980:</b>In 1988, Buffett started accumulating shares of <b>Coca-Cola</b> for Berkshire Hathaway. After several large purchases, Berkshire Hathaway owned 7% of the company worth $1.02 billion. Buffett has a long history with Coca-Cola, once selling bottles for a penny profit. Berkshire Hathaway still owns 800 million shares of KO, worth nearly $18 billion.</p><p><b>1990:</b>Geico insurance has been one of the biggest pieces for Berkshire Hathaway since it acquired full control in the 1990s. Berkshire acquired the insurance company by buying out the 49% it did not own up until this point.</p><p>Buffett had been an investor of Geico shares dating back to 1951. Benjamin Graham, Buffett’s mentor and professor, was once the chairman of Geico. The insurance company is forever linked to two of the most well-known investors.</p><p><b>2000:</b>The 2000s represented a great period of fortune and giving for Warren Buffett. In 2008, Buffett became the richest man in the world, with Forbes valuing his wealth at $62 billion. Buffett took over the top spot from <b>Microsoft</b> founder Bill Gates, who had held the number one position for thirteen consecutive years. Buffett pledged in 2006 to give away the majority of his wealth after his death, including 85% to the Bill and Melinda Gates Foundation.</p><p><b>2010:</b>Berkshire Hathaway started buying stock in <b>Apple</b> in 2016. Buffett has since admitted he wishes he would have bought shares earlier.</p><p>“It’s probably the best business I know in the world,” Buffett told CNBC. Berkshire bought shares of Apple again throughout the decade to make it one of the biggest pieces of the investment portfolio.</p><p>“I don’t think of Apple as a stock. I think of it as a third business,” Buffett told CNBC referring to Apple being the company’s third-biggest holding behind Geico and railroad interests.</p><p><b>2020:</b>Warren Buffett showed an investor lesson when he sold out of his stake in the big four airlines. A longtime vocal non-supporter of buying airline stocks, he sold his stake worth around $7 billion at a loss.</p><p>He ditched his stakes in <b>American Airlines</b>, <b>Delta Air Lines</b>, <b>Southwest Airlines</b>, and <b>United Airlines</b> believing passenger numbers would not recover after the pandemic. He also cited carriers could be left with too many planes and would be hurt financially due to government loans.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","BRK.B":"伯克希尔B"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180044728","content_text":"Legendary investor Warren Buffett was born Aug. 30, 1930. The “Oracle of Omaha” turns 91 today and has now lived through 10 decades.Buffett has been one of the greatest investors of the last six decades and remains the active chairman of Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B). This article will showcase a highlight from each decade of Buffett’s personal and investment career.1930:Warren Buffett was born Aug. 30, 1930. His father Howard was a former stockbroker, which would have a huge influence on Buffett’s decision to get involved with the business.1940:Buffett purchased his first stock at the age of 11. The purchase was for three shares of Cities Service Preferred, a natural gas company. Buffett bought the shares at $38 only to see them soon drop to $27 each. He waited until they hit $40 to sell for a profit. Shares later hit $200 each, which Buffett has since cited as a lesson on patience in investing.1950:Despite his growing wealth, Buffett has lived in the same house in Nebraska, Omaha since 1958. The home was purchased for $31,500. Adjusted for inflation, that would be the equivalent of over $280,000 today.1960:By the year 1965, Buffett had assumed control of textiles company Berkshire Hathaway thanks to acquiring 49%. He became a director of the company and would work on gaining full control and also diversifying the company away from textiles.1970: Buffett became the author of the annual Berkshire Hathaway letters in the 1970s. These letters are considered must-reads for investors and every year, what Buffett writes to shareholders is analyzed with great detail. The letters include explanations for investments or why items were sold. The letters also include life lessons and memorable quotes from the “Oracle of Omaha.”1980:In 1988, Buffett started accumulating shares of Coca-Cola for Berkshire Hathaway. After several large purchases, Berkshire Hathaway owned 7% of the company worth $1.02 billion. Buffett has a long history with Coca-Cola, once selling bottles for a penny profit. Berkshire Hathaway still owns 800 million shares of KO, worth nearly $18 billion.1990:Geico insurance has been one of the biggest pieces for Berkshire Hathaway since it acquired full control in the 1990s. Berkshire acquired the insurance company by buying out the 49% it did not own up until this point.Buffett had been an investor of Geico shares dating back to 1951. Benjamin Graham, Buffett’s mentor and professor, was once the chairman of Geico. The insurance company is forever linked to two of the most well-known investors.2000:The 2000s represented a great period of fortune and giving for Warren Buffett. In 2008, Buffett became the richest man in the world, with Forbes valuing his wealth at $62 billion. Buffett took over the top spot from Microsoft founder Bill Gates, who had held the number one position for thirteen consecutive years. Buffett pledged in 2006 to give away the majority of his wealth after his death, including 85% to the Bill and Melinda Gates Foundation.2010:Berkshire Hathaway started buying stock in Apple in 2016. Buffett has since admitted he wishes he would have bought shares earlier.“It’s probably the best business I know in the world,” Buffett told CNBC. Berkshire bought shares of Apple again throughout the decade to make it one of the biggest pieces of the investment portfolio.“I don’t think of Apple as a stock. I think of it as a third business,” Buffett told CNBC referring to Apple being the company’s third-biggest holding behind Geico and railroad interests.2020:Warren Buffett showed an investor lesson when he sold out of his stake in the big four airlines. A longtime vocal non-supporter of buying airline stocks, he sold his stake worth around $7 billion at a loss.He ditched his stakes in American Airlines, Delta Air Lines, Southwest Airlines, and United Airlines believing passenger numbers would not recover after the pandemic. He also cited carriers could be left with too many planes and would be hurt financially due to government loans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898268088,"gmtCreate":1628501719344,"gmtModify":1703507161164,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"check","listText":"check","text":"check","images":[{"img":"https://static.tigerbbs.com/65c3b9482b42ce2e2c8b12bb2a4e0b53","width":"1080","height":"2265"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898268088","isVote":1,"tweetType":1,"viewCount":580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":9914721262,"gmtCreate":1665369283557,"gmtModify":1676537593629,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9914721262","repostId":"9914484075","repostType":1,"repost":{"id":9914484075,"gmtCreate":1665357653098,"gmtModify":1676537589922,"author":{"id":"3583230105554843","authorId":"3583230105554843","name":"Keeley","avatar":"https://community-static.tradeup.com/news/425dded61ea0f1ec6aa9c19997bc9677","crmLevel":5,"crmLevelSwitch":0},"themes":[],"title":"Stocks Technical Analysis #AMC #MSFT #AAPL","htmlText":"Find out more about me here (YouTube/Instagram/Telegram): https://www.linktr.ee/keeleytan If you find my post helpful, I’ll be grateful and appreciate it if you could leave me a like on this post, and follow me for future posts like this. If you have any comments/feedback, feel free to use the link above to Google form. Free signal service on discord is officially up. If interested, head to my discord to check it out! <a target=\"_blank\" href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>&nbsp; Price is playing out as analyzed last week. I'm expecting price to go lower to take the lows at 5.96 after mitigating the current POI at 6.59, no changes to my previous expectations. https://www.tradingview.com/chart/AMC/EYUzXC3b-AMC-Analysis/","listText":"Find out more about me here (YouTube/Instagram/Telegram): https://www.linktr.ee/keeleytan If you find my post helpful, I’ll be grateful and appreciate it if you could leave me a like on this post, and follow me for future posts like this. If you have any comments/feedback, feel free to use the link above to Google form. Free signal service on discord is officially up. If interested, head to my discord to check it out! <a target=\"_blank\" href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>&nbsp; Price is playing out as analyzed last week. I'm expecting price to go lower to take the lows at 5.96 after mitigating the current POI at 6.59, no changes to my previous expectations. https://www.tradingview.com/chart/AMC/EYUzXC3b-AMC-Analysis/","text":"Find out more about me here (YouTube/Instagram/Telegram): https://www.linktr.ee/keeleytan If you find my post helpful, I’ll be grateful and appreciate it if you could leave me a like on this post, and follow me for future posts like this. If you have any comments/feedback, feel free to use the link above to Google form. Free signal service on discord is officially up. If interested, head to my discord to check it out! $AMC Entertainment(AMC)$ Price is playing out as analyzed last week. I'm expecting price to go lower to take the lows at 5.96 after mitigating the current POI at 6.59, no changes to my previous expectations. https://www.tradingview.com/chart/AMC/EYUzXC3b-AMC-Analysis/","images":[{"img":"https://community-static.tradeup.com/news/87c82ac8ffdef891beacca2139e81437"},{"img":"https://community-static.tradeup.com/news/d3b45cfb4b54769e37227ef989830730"},{"img":"https://community-static.tradeup.com/news/c3e5f47bb3d34b2d086b7d2a38936bd9"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9914484075","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9079935043,"gmtCreate":1657145182182,"gmtModify":1676535955360,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9079935043","repostId":"1161524120","repostType":4,"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081497610,"gmtCreate":1650262073244,"gmtModify":1676534681757,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","crmLevel":2,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081497610","repostId":"9081196317","repostType":1,"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}